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FXR agonist obeticholic acid 
reduces hepatic inflammation 
and fibrosis in a rat model of toxic 
cirrhosis
Len Verbeke1, Inge Mannaerts2, Robert Schierwagen3, Olivier Govaere4, Sabine Klein3, 
Ingrid Vander Elst1, Petra Windmolders1, Ricard Farre5,6, Mathias Wenes7,8, 
Massimiliano Mazzone7,8, Frederik Nevens1, Leo A. van Grunsven2, Jonel Trebicka3 & 
Wim Laleman1
Hepatic inflammation drives hepatic stellate cells (HSC), resulting in liver fibrosis. The Farnesoid-X 
receptor (FXR) antagonizes inflammation through NF-κB inhibition. We investigated preventive and 
therapeutic effects of FXR agonist obeticholic acid (OCA) on hepatic inflammation and fibrosis in toxic 
cirrhotic rats. Cirrhosis was induced by thioacetamide (TAA) intoxication. OCA was given during or after 
intoxication with vehicle-treated rats as controls. At sacrifice, fibrosis, hemodynamic and biochemical 
parameters were assessed. HSC activation, cell turn-over, hepatic NF-κB activation, pro-inflammatory 
and pro-fibrotic cytokines were determined. The effect of OCA was further evaluated in isolated 
HSC, Kupffer cells, hepatocytes and liver sinusoidal endothelial cells (LSEC). OCA decreased hepatic 
inflammation and fibrogenesis during TAA-administration and reversed fibrosis in established cirrhosis. 
Portal pressure decreased through reduced intrahepatic vascular resistance. This was paralleled by 
decreased expression of pro-fibrotic cytokines (transforming growth-factor β, connective tissue growth 
factor, platelet-derived growth factor β-receptor) as well as markers of hepatic cell turn-over, by 
blunting effects of pro-inflammatory cytokines (e.g. monocyte chemo-attractant protein-1). In vitro, 
OCA inhibited both LSEC and Kupffer cell activation; while HSC remained unaffected. This related 
to NF-κB inhibition via up-regulated IκBα. In conclusion, OCA inhibits hepatic inflammation in toxic 
cirrhotic rats resulting in decreased HSC activation and fibrosis.
Conditions of sustained hepatic injury are associated with increasing hepatocyte loss and scar formation, result-
ing in progressive accumulation of fibrosis within the liver parenchyma1. The main cellular driver of fibrosis 
in this process has been shown to be the hepatic stellate cell (HSC)2. HSC are in turn incited by stimulated 
Kupffer cells (KC) and liver sinusoidal endothelial cells (LSEC) via paracrine production of pro-inflammatory and 
pro-fibrotic cytokines such as connective tissue growth factor (CTGF), transforming growth factor-β (TGF-β ) 
and platelet-derived growth factor (PDGF). Under these conditions, HSC proliferate and transdifferentiate into 
myofibroblasts, deposing collagen type I and III as well as fibronectin in the hepatic extracellular matrix (ECM), 
eventually producing pro-fibrotic cytokines also in an autocrine fashion3. The development of hepatic fibrosis, 
and ultimately cirrhosis, is considered detrimental in the natural evolution of chronic liver disease as it interferes 
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with the normal hepatic metabolic function and hampers hepatic portal blood flow which increases intrahepatic 
vascular resistance (IHVR), and ultimately leads to portal hypertension and its complications4.
For these reasons, interfering with the process of fibrogenesis has become an appealing therapeutic target 
for future treatment of chronic liver disease; especially since for many prevalent liver disorders such as primary 
biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH), treatment of the underlying liver disease 
remains extremely challenging5–9. From this perspective, the farnesoid-X receptor (FXR) appears a promising 
target. This nuclear receptor, which is essentially a bile-acid responsive transcription regulator of bile and lipid 
metabolism, has recently also been correlated with the development of hepatic fibrosis10–12. As an example hereof, 
FXR knock-out mice over time display increased hepatic inflammation and fibrosis13,14. Furthermore, the acti-
vation of FXR by means of highly potent and selective FXR agonists such as obeticholic acid (OCA) has been 
suggested to reduce fibrosis in two experimental models of early-stage liver fibrosis either by 2 weeks bile-duct 
ligation or after 12 weeks of treatment with porcine serum12. Contrarily, Fickert et al. have shown that after 
FXR-knock-out, decreased hepatic FXR expression is protective of fibrosis progression in experimental cholesta-
sis, while it is totally unrelated to fibrogenesis under non-cholestatic conditions such as carbon tetrachloride 
(CCl4) or S. mansoni-infection15. Furthermore, we and others were unable to detect direct effects of FXR stimu-
lation on human and rodent HSC activation and hypercontractility in vitro15,16. Conceptually however, the FXR 
pathway might also decelerate fibrogenesis indirectly by targeting hepatic inflammation since it has been shown 
to reciprocally counter-balance nuclear factor-kappa beta (NF-κ B) mediated- transcription of pro-inflammatory 
cytokines in a variety of cell types13,17,18.
Given this background and controversies, we aimed to explore, both prophylactically as therapeutically, the 
effects of FXR-agonism by means of OCA, an oral first-in-class FXR agonist, on hepatic inflammation and fibrosis 
in a model of toxic non-cholestatic cirrhosis by means of thioacetamide ingestion in rats and to correlate these 
findings to different cytokines and parenchymal and non-parenchymal cell types exposed to FXR-agonism in vitro.
Materials and Methods
Animals. 60 Male Wistar rats (Janvier, France) weighing 200–250 grams were randomly allocated to 4 exper-
imental groups (Supplementary Figure S1). In all animals, thioacetamide was used as hepatoxin, which was val-
idated earlier19 to induce histology-proven cirrhosis after 18 weeks of administration in drinking water. In a 
first, prophylactic arm of the study, either vehicle (group 1, TAA) or 10 mg/kg of the FXR agonist OCA (group 2, 
TAA + OCA) was administered by gavage every 2 days during the last 4 weeks of the TAA intoxication proto-
col (thus in the last phase of advanced fibrosis/cirrhogenesis). In a second, therapeutic arm of the study, again 
either vehicle (group 3, TAA + 4) or 10 mg/kg of the FXR agonist OCA (group 4, TAA + 4 + OCA) was admin-
istered through gavage every 2 days for 4 weeks after stopping the 18 week-regimen of TAA intoxication (thus 
after obtaining cirrhosis). Parenchymal liver cells were isolated from Balb/cByJ mice (25–35 g, Charles River 
Laboratories, France). Approval for all experiments was obtained from the KULeuven Animal Ethics Committee 
and all experiments were conducted according to the approved guidelines.
In vivo hemodynamic and biochemical parameters. At sacrifice, portal pressure (PP), mean arterial 
pressure (MAP) and mesenteric blood flow (MBF) were measured as described16. Samples were collected by aor-
tic puncture in heparinized tubes and analyzed for routine plasma hepatic enzymes by automated procedure19. 
Hepatic tissue samples were snap-frozen for molecular analysis.
Isolation of mouse liver cells and in vitro stimulation experiments. HSCs, liver sinusoidal endothe-
lial cells (LSEC) and hepatocytes (HEP) were isolated for mouse liver and cultured according to validated 
protocols20,21. Kupffer cells (KC) were isolated by fluorescence-activated cell sorting after collagenase/pronase per-
fusion, using an F4/80 antibody (Invitrogen, USA). Cell purity and functionality were confirmed on morphology 
and by quantitative polymerase chain reaction (qPCR) for following marker genes (Supplementary Methods S2): 
Cyp3a11 (HEP), CD32b (LSEC), desmin and Acta2 (HSC)22. 2 Hours after isolation (4 hours for HEP), cells were 
washed and either solvent or OCA was added to the medium at concentrations of 0.1, 1 and 10 μ M, together with 
vehicle, 1 mg/mL TGF-β 1 (R&D Systems, Wiesbaden-Nordenstadt, Germany), TNF-α or LPS. All cells were col-
lected for molecular analysis 24 h after incubation, except for culture-activated HSC that were further stimulated 
for 7 days. LX2 cells were provided by Vijay H. Shah (Mayo Clinic, Rochester, NY), originally established by Scott 
Friedman23.
Assessment of hepatic fibrosis by image analysis. Fresh liver samples were fixed in formaldehyde 6%, 
paraffin embedded, sectioned and Sirius-red stained. Areas of fibrosis were detected and scored with automated 
color threshold image analysis by use of an Olympus BX60 microscope and Stream essentials software (version 
1.9 [2013]; Olympus, Belgium). Slides from both the left lateral and the middle hepatic lobe were then evaluated 
per rat and blinded to the investigator analyzing the samples. 10 consecutive image-centered portal tracts were 
scored per rat for fibrosis and were represented as a percentage of the total liver parenchyma at 10X magnification.
Caspase-3 Immunohistochemistry. 5 μ m-thick frozen tissue samples were stained using the BondTM 
Polymer Refine Red Detection kit on the Bond Max autostainer (Leica). Primary antibody was directed against 
cleaved Caspase-3 (1/100, Cell Signaling). Positive cells were quantified in five higher power fields.
Hepatic hydroxyproline content. Three corresponding segments (200 mg) from the middle hepatic lobe 
were hydrolyzed in HCl (6N), filtered and incubated with chloramine T (2.5 mM) and Ehrlich’s reagent7. The 
hepatic hydroxyproline content was determined photometrically in the acquired liver hydrolysates by absorption 
measurements at 558 nm. Results are expressed as μ g/g of wet liver tissue.
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RT-PCR. Supplementary Methods S3.
Western blot. Supplementary Methods S4.
NF-κB activity assay. A liver specimen of about 100 mg was lysed in 1,5 ml RIPA buffer (50 mM Tris pH8, 
150 mM NaCl, 0,5% SDS, 1% triton, 5 mM EDTA, 0,5% Na-deoxycholate) containing protease and phosphatase 
inhibitors (Roche, Belgium), and using Lysing matrix D (MP-biomedicals, USA) and a Ribolyser (Bio-rad, 
Belgium) 3 × 60 s at maximum speed. Protein concentration was determined using the Pierce BCA Protein Assay 
Kit (Thermo Scientific, USA). 30 μ g of protein was used to determine NF-kB activity using the Active Motif 
(Belgium) p65-TransAM kit following the manufacturers’ protocol.
In situ-liver perfusion. To evaluate total intrahepatic vascular resistance (IHVR), a flow-controlled per-
fusion study of the liver was performed with a continuously oxygenated and heated Krebs buffer solution as 
described16,19,24. After a 20 minute stabilization period, flow rates were increased by 5 ml/min every each 5 minutes 
starting at a 30 ml/min flow rate. Subsequent elevations in perfusion pressure were assessed at the level of the 
portal inflow catheter and as such reflective of total IHVR.
Statistics. Data were all normally distributed. As such, data were expressed as means ± standard error of 
means (SEM) and subjected to parametrical statistics. Comparing two unpaired groups, the Student t test was 
applied; for comparison of multiple groups, a one-way analysis of variance was applied. If positive, a subsequent 
pair-wise comparison was performed by means of Bonferroni t-testing. Correlations were assessed by linear 
regression analysis. P-values below 0.05 were considered statistically significant. Statistical analysis was per-
formed by means of GraphPad Prism software (version 6.02[2013]; GraphPad Software Inc., USA).
Results
FXR agonist OCA reduces fibrosis in TAA cirrhotic rats. After 18 weeks of TAA intoxication, all vehi-
cle-treated animals had developed cirrhosis, as confirmed by Sirius-red-stained liver histology (Fig. 1A). There 
was no difference in mortality between OCA-treated and -untreated animals (88% overall survival). Physical 
and biochemical variables amongst different groups are given in Table 1. A clear decrease in plasma alanine 
aminotransferase (ALT) levels was observed after OCA treatment in the therapeutic study arm (97 ± 4 vs. 79 ± 4 
IU/L in TAA + 4 vs. TAA + 4 + OCA, n = 6 and 9 resp.; P = 0.01; Table 1). Upon image analysis, the amount of 
fibrosis is clearly decreased in both the prophylactic (16.5 ± 1.2 vs. 12.2 ± 1.1% in TAA vs. TAA + OCA; n = 8 in 
both groups; P = 0.01; Fig. 2B) and the therapeutic (17.1 ± 1.7 vs. 10.3 ± 0.9% in TAA + 4 vs. TAA + 4 + OCA; 
n = 7 and 9 resp.; P < 0.001; Fig. 1B) study groups upon OCA treatment. The latter is confirmed by a decrease in 
hepatic hydroxyproline content (691 ± 91 vs. 473 ± 24 in TAA + 4 vs. TAA + 4 + OCA; n = 6 and 7 resp.; P = 0.01; 
Fig. 1C) and a decreased hepatic collagen type I mRNA expression (Fig. 1D), (Fig. 1A–D, Table 1).
The reduction in hepatic fibrosis by OCA is associated with a decreased portal pressure through 
reduced intrahepatic vascular resistance. Upon treatment with OCA, portal pressure is significantly 
decreased in the therapeutic study arm (14.9 ± 0.7 vs. 12.7 ± 0.3 mm Hg in TAA + 4 vs. TAA + 4 + OCA; n = 6 
and 7 resp.; P = 0.01; Fig. 2A), while mesenteric blood flow was elevated as expected given the phenomenon of 
splanchnic hyperemia, it remained unaffected by OCA gavage in both groups. Interestingly, the overall degree of 
fibrosis correlated nicely with the degree of portal hypertension in cirrhotic rats (R2 = 0.38; P < 0.001; Fig. 2B). 
Upon liver perfusion, overall perfusion pressures were markedly lower for any given flow following OCA treat-
ment in both the prophylactic and the therapeutic study arm at any flow rate, indicative of a decreased total IHVR 
(1.05 ± 0.08 vs. 0.78 ± 0.05 and 1.22 ± 0.11 vs. 0.99 ± 0.05 mm Hg*min*100 g/ml in TAA vs. TAA + OCA and 
TAA + 4 vs. TAA + 4 + OCA; n = 5 in all groups except TAA + 4 + OCA: n = 4; P < 0.001; Fig. 2C), (Fig. 2A–C).
In cirrhotic rat livers, OCA decreases markers of HSC activation, markers of apoptosis and 
proliferation, and also the expression of pro-inflammatory and pro-fibrotic cytokines. In 
the therapeutic study arm, a significant decreased hepatic protein level of alpha-smooth muscle actin (α -SMA) 
was observed on Western blot, indicative of decreased HSC activation (P < 0.02; Fig. 3A). In accordance with 
these findings, the hepatic expression of connective tissue growth factor (CTGF), one of the main pro-fibrotic 
cytokines driving hepatic fibrogenesis, was reduced in both arms (P < 0.03; Fig. 3B). In the therapeutic study 
arm, this was further associated with a decreased expression of both transforming growth factor-β 1 (TGF-β 1) 
and platelet-derived growth factor-beta receptor (PDGFβ -R) (P < 0.05 and 0.02 resp., Fig. 3B). Additionally, the 
expression of tissue inhibitor of metallopeptidase-1 (TIMP-1), a known inhibitor of metalloproteinases and thus 
ECM degradation, appears down-regulated in both study arms (P < 0.04; Fig. 3B). At the protein level, prolif-
erating cell nuclear antigen (PCNA), a validated global marker of pro-inflammatory and pro-fibrotic cell pro-
liferation7, was decreased in cirrhotic rats following OCA treatment (P < 0.02; Fig. 3C). Also poly ADP ribose 
polymerase-1 (PARP-1), known substrate of active caspase-3 and thus a marker of apoptosis, displays decreased 
cleavage upon OCA exposure, illustrated by a decrease in the small (24 kD) cleaving fragment compared to the 
large uncleaved PARP-1 protein (118 kD) (P < 0.03; Fig. 3D). The latter was confirmed by a clear decrease of 
immunohistochemical staining positivity for caspase-3 in both the prophylactic and the therapeutic study group 
(P ≤ 0.05; Fig. 3E), (Fig. 3A–E).
OCA does not directly affect either rodent or human HSC in vitro. In freshly isolated, quiescent pri-
mary HSC, the in vitro expression of pro-inflammatory and pro-fibrotic cytokines was not significantly affected 
by stimulation with 0.1–10 μ M OCA (Fig. 4A). While HSC displayed clearly activated phenotype after 7 days of 
culture-growth, with a 2000-fold increase in α -SMA expression, they remained unaffected by OCA (Fig. 4A). 
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Also upon in vitro stimulation with tumor necrosis factor-alpha (TNF-α ) or lipopolysaccharides (LPS), primary 
HSC remained unresponsive to OCA (Fig. 4B). In the human hepatic stellate cell line LX223, activation was seen 
following in vitro stimulation with 1 mg/mL transforming growth factor-beta1 (TFB-β 1) with increased expres-
sion of α -SMA and col1a1. This was unaltered by simultaneous incubation with 0.1–10 μ M OCA, with the excep-
tion of slightly decreased col1a1 expression in TGF-β 1 stimulated LX2 cells at the highest concentration of OCA 
10 μ M (P ≤ 0.05; Fig. 4C). Finally, OCA failed to affect apoptosis amongst LX2 cells in vitro, neither in the pres-
ence nor absence of TGF-β 1 (Fig. 4D), (Fig. 4A–D).
OCA prevents the in vitro activation of Kupffer cells (KC) and liver sinusoidal endothelial cells 
(LSEC) by LPS or TNF-α. Primary hepatocytes (HEP) respond to LPS and especially TNF-α in vitro with 
increased expression of MCP-1, yet this remained unaffected by co-incubation with 0.1–10 μ M OCA (Fig. 5A). 
Figure 1. Effects of FXR agonist OCA on fibrosis in TAA rats. (A) Representative macroscopic and 
microscopic (Sirius red stain with subsequent image analysis) illustration of a vehicle- vs. OCA-treated rat in 
the therapeutic arm of the study. (B) Image analysis data showing a decreased detection of fibrosis in both the 
prophylactic and the therapeutic study groups (n = 7–9 animals per group). (C) Following OCA treatment, 
hepatic hydroxyproline content is significantly decreased in the therapeutic study arm and nearly significant in 
the prophylactic arm of the study, confirming decreased hepatic fibrosis (n = 6–8 animals per group). (D) In the 
therapeutic study, this is associated with a decreased hepatic expression of col1a1 mRNA (n = 6–8 animals per 
group). FXR, Farnesoid-X receptor; TAA, thioacetamide; col1a1, collagen type I.
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While OCA failed to affect the expression of pro-inflammatory and pro-fibrotic cytokines in unstimulated LSEC 
and KC, it prevented the increased expression of MCP-1 following stimulation with TNF-α and LPS or TNF-α 
alone in LSEC and KC respectively (P < 0.05; Fig. 5B,C), (Fig. 5A–C).
Reduced hepatic fibrosis by OCA is associated with decreased hepatic NF-κB pathway activity 
through up-regulated IκBα. Upon treatment with OCA, decreased p65 (RelA) activation was indicative 
for decreased hepatic NF-κ B pathway activity in the therapeutic study arm (P < 0.04, Fig. 6A). In the prophylactic 
study group, differences failed to reach statistical significance. Hepatic levels of the NF-κ B pathway inhibitory 
protein, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (Iκ Bα ), were clearly 
up-regulated in the prophylactic study group and nearly reached statistical significance in the therapeutic study 
arm (P < 0.01 and P = 0.07 respectively, Fig. 6B), (Fig. 6A,B).
Discussion
The development and progression of hepatic fibrosis, driven by chronic liver injury and subsequent inflammation, 
is considered a driving force behind many lethal complications in chronic liver disease, such as liver failure, portal 
hypertension and hepatocellular carcinoma25–33. As the main cellular source for hepatic fibrosis, many attempts 
have since then focused on HSCs both in vitro and in translational animal studies as a target for anti-fibrotic ther-
apy, yet none of them have really made it into clinical practice7,9,34,35.
In this study, we demonstrated for the first time that by targeting hepatic inflammation by means of obet-
icholic acid (OCA), a highly potent and selective first-in-class agonist of the nuclear bile acid receptor FXR, fibro-
sis can be decreased, both in the process of cirrhogenesis, yet also after cirrhosis has been fully established. This 
decrease in fibrosis is clinically relevant since it was paralleled by a firm decrease in total intrahepatic vascular 
resistance (IHVR) and thus portal hypertension. While we have previously shown that acute treatment with OCA 
decreases IHVR with 16% in TAA cirrhotic rats16, following long-term treatment within the same model we were 
now able to confirm these previous findings and document a further reduction of IHVR up to 25%. This suggests 
that in the latter now not only the active but also the passive component (i.e. fibrosis) of IHVR is affected. This is 
further substantiated by the linear correlation between hepatic fibrosis and portal pressure.
Until now, the antifibrotic potential of FXR agonists has proven highly controversial. While Fiorucci et al.12 
and Úbeda et al.36 reported decreased hepatic fibrosis upon preventive OCA-treatment in porcine serum-induced 
and CCl4–induced liver fibrosis respectively, their findings were contrasted by the data of Fickert et al.15, finding 
unaltered effect on fibrosis upon CCl4- or S. mansoni-mediated liver injury in animals with genetic FXR-loss. 
Furthermore, we and others failed to detect functional levels of FXR and FXR pathway activity in isolated HSC 
in vitro15,16. A further confounding factor in these apparently conflicting data might be the recently revealed 
beneficial effects of FXR agonists on gut barrier dysfunction, microbiota and bacterial translocation from the gut 
which in turn might result in reduced liver damage and a secondary decrease in hepatic fibrosis, especially in the 
CCl4-model36–38. In this study, we opted to induce cirrhosis by means of TAA because we have previously shown 
bacterial translocation to be absent in TAA cirrhotic rats, largely avoiding cross-talk from the gut-liver axis in 
this manner38.
In this study, we showed that FXR activation is quickly lost in HSC upon-culture activation in vitro 
(Supplementary Figure S5) and confirmed that FXR agonists are not able to reactivate the FXR pathway, both 
in human and murine HSC, independent of a quiescent, activated or stimulated state. Nevertheless, molecu-
lar data from liver tissue in our rats clearly suggest decreased HSC activation, with decreased protein levels of 
alpha-smooth muscle actin (α -SMA) as well as a decreased expression of type I collagen upon OCA treatment. 
Taken together, these findings imply that the cellular target for FXR-agonism to ultimately decrease hepatic 
fibrosis in our rat model of toxic cirrhosis is to be searched for further upstream in the cascade of HSC acti-
vation. For this reason, we isolated different both parenchymal and non-parenchymal hepatic cell types from 
healthy mouse liver: hepatocytes, Kupffer cells and LSEC, which were exposed to increasing concentrations of 
OCA in vitro, cultured under both stimulated and unstimulated conditions. While we were unable to isolate 
cells from cirrhotic murine livers, a possible shortcoming in this study, we mimicked the cirrhotic environ-
ment by exposing different hepatic cell types to different pro-inflammatory stimuli in vitro. Interestingly, we 
found that OCA dose-dependently inhibited the TNF-α or bacterial endotoxin (LPS)-stimulated expression of 
MCP-1 in both Kupffer cells and LSEC. This finding is particularly important given the potential for a decrease 
in MCP-1 to inhibit the chemotactic and fibrogenic potential of HSC and the simultaneous observation of 
TAA 
(n = 8)
TAA + OCA 
(n = 9) P-value
TAA + 4 
(n = 6)
TAA + 4 + OCA 
(n = 9) P-value
Body weight (g) 319 ± 11 302 ± 11 0.27 395 ± 9 410 ± 12 0.38
Overall average dose TAA (g/L) 520 ± 13 478 ± 23 0.15 478 ± 19 450 ± 21 0.31
Liver weight 22 ± 2 22 ± 2 0.89 24 ± 2 22 ± 2 0.32
Albumin (g/L) 33.5 ± 0.8 35.1 ± 1.2 0.28 35.2 ± 1.0 36.6 ± 0.7 0.45
AST (IU/L) 85 ± 4 87 ± 7 0.76 100 ± 4 93 ± 4 0.68
ALT (IU/L) 75 ± 4 66 ± 3 0.34 97 ± 4 79 ± 4 *0.01
Bilirubin (mg/dL) 0.3 ± 0.1 0.3 ± 0.2 0.92 0.0 ± 0.0 0.0 ± 0.1 0.90
Table 1. Physical and biochemical findings in blood plasma amongst different experimental groups. TAA, 
thioacetamide; OCA, obeticholic acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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decreased MCP-1 in our OCA-treated rat livers9,39. The functionality of FXR in the sinusoidal endothelium is 
in line with our earlier findings, showing strong effects of OCA on HSC hypercontractility, through an equally 
indirect release of nitric oxide by LSEC16. Of further importance, also Kupffer cells, the main cellular gatekeepers 
of hepatic innate immunity were targeted by OCA40. In isolated Kupffer cells, this did not only translate in a 
decrease of pro-inflammatory cytokines such as MCP-1, but also in anti-inflammatory cytokines such as IL-10 
(Supplementary Figure S6). Again, this is in line with previous findings exploring the effects of OCA on intestinal 
immunity in cholestatic rats38. The anti-inflammatory effects observed in vitro were further again also confirmed 
in our OCA-treated rat livers, with decreased hepatic necro-inflammation (with a significant decrease in plasma 
ALT-levels) and an overall decreased expression of crucial pro-inflammation and pro-fibrotic cytokines such as 
Figure 2. Hemodynamic parameters and intrahepatic vascular resistance. (A) Portal pressure is decreased 
in TAA cirrhotic rats (therapeutic study arm) following 4 weeks of OCA treatment, without affecting mesenteric 
blood flow (n = 6–8 and 4–5 rats per groups, respectively). (B) Portal pressure is highly and significantly 
correlated with the amount of hepatic fibrosis, as assessed by image analysis in rats from all groups, regardless 
of OCA treatment. (C) In-situ liver perfusion data showing decreased perfusion pressure at each flow rate in 
both the preventive and therapeutic study arm, indicative of a decreased intrahepatic vascular resistance. TAA, 
thioacetamide; OCA, obeticholic acid; MBF, mesenteric blood flow.
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Figure 3. Hepatic levels of HSC activation marker α-SMA and cytokines involved in fibrogenesis, 
fibrinolysis, inflammation, proliferation and apoptosis. (A) In the therapeutic study arm, the hepatic 
protein levels of α -SMA, assessed by Western blot, are clearly decreased following OCA treatment indicative 
of decreased HSC activation (n = 4 per group). (B) RT-PCR data showing decreased expression of pro-fibrotic 
(CTFG, PDGF-R, TGF-β 1), anti-fibrinolytic (TIMP-1) as well as pro-inflammatory cytokines in either the 
therapeutic study arm alone or both upon OCA treatment (n = 6–8 per group). (C) Western blot data showing 
decreased levels of proliferation marker PCNA in OCA treated rats from the therapeutic study arm. (D) Western 
blot data showing a decrease in the small degradation fragment (24 kD) of PARP-1 in OCA treated rats from 
the therapeutic study arm, indicative of decreased capase-3 activity. (E) Immunohistochemical staining for 
caspase-3 showing decreased caspase-3 positivity in both the prophylactic and therapeutic study arm. HSC, 
hepatic stellate cell; α -SMA, alpha-smooth muscle actin; OCA, obeticholic acid; RT-PCR, reverse-transcriptase 
polymerase chain reaction; CTGF, connective tissue growth factor; PDGF-R, platelet-derived growth factor-
beta receptor; TGF-β 1, Transforming growth factor-β 1; TIMP-1, tissue inhibitor of metallopeptidase-1; MCP, 
monocyte chemo-attractant protein-1; iNOS, inducible nitric oxide synthase; IFN-γ , interferon-gamma; PCNA, 
proliferating cell nuclear antigen; PARP-1, poly ADP ribose polymerase-1.
www.nature.com/scientificreports/
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Figure 4. In vitro response to OCA in both quiescent and activated, both primary murine and human LX2 
HSC lines. (A) The expression of pro-inflammatory and pro-fibrotic cytokines is unaltered in both quiescent 
freshly collected, as well as 7-day culture-activated HSC upon stimulation in vitro with 0.1–10 μ M OCA.  
(B) OCA does not alter the expression of MCP-1 or MMP-13 in primary HSC stimulated with LPS or TNF-α .  
(C) In the human HSC line LX2, stimulation with 1 mg/mL TGF-β 1 induces the expression of α -SMA and 
col1a1, which cannot be prevented by co-stimulation with OCA; with the exception of col1a1 expression at 
10 μ M OCA. (D) OCA does not affect the in vitro fraction of apoptotic LX2 cells, neither in basic nor  
0.1 mg/ml TGF-β stimulated conditions. FXR, Farnesoid-X receptor; SHP, small heterodimer partner; α -SMA, 
alpha-smooth muscle actin; qHSC, quiescent hepatic stellate cell, aHSC, activated hepatic stellate cell; OCA, 
obeticholic acid; RT-PCR, reverse-transcriptase polymerase chain reaction; col1a1, collagen type I; MCP-1,  
monocyte chemo-attractant protein-1; PDGF-R, platelet-derived growth factor-beta receptor; TGF-β ,  
transforming growth factor-β ; IFN-γ , interferon-gamma; MMP-13, matrix metallopeptidase 13; TNF-α , 
tumor necrosis factor-alpha; LPS, lipopolysaccharides.
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CTGF and TGF-β . Interestingly in our study, also the expression of TIMP-1, a known inhibitor of matrix metal-
loproteinases secreted amongst others by Kupffer cells, appears decreased upon OCA treatment in cirrhotic rats. 
In this respect, decreased TIMP-1 suggests an additional increase in extracellular matrix degradation, further 
ameliorating the existing misbalance between accumulation and degradation of collagens typical of cirrhosis. 
The finding of decreased TIMP-1 might be of further relevance in this study because it is known to also exert an 
anti-apoptotic effect on HSC in vitro41. The suggestion of decreased hepatic cell proliferation and apoptosis is 
further supported in our study by the finding of decreased hepatic PCNA levels as well as decreased enzymatic 
degradation of PARP-1, a known substrate of caspase-3, as well as a decreased caspase-3 immunohistochemical 
staining positivity in OCA treated cirrhotic rats7. These findings suggest that the documented resolution of fibro-
sis observed in cirrhotic rats not only relates to the inhibition of pro-fibrotic signals on HSC as such, but is also 
critically influencing other determinants of hepatic fibrosis such as ECM degradation, inflammation, prolifera-
tion and apoptosis and adds up to the pleiotropic effects of FXR-agonism.
Finally, given the observed overall hepatic anti-inflammatory effect, we focused on the central orchestrator, 
the NF-κ B pathway. This pathway, which is a common pro-inflammatory pathway shared not only by a variety of 
immune cells but also by endothelial cells and hepatocytes amongst others42–45, is highly involved in the hepatic 
inflammatory response and subsequent hepatic stellate cell activation46,47. Previous studies in other settings have 
shown the relation of FXR to the NF-κ B pathway to be one of important mutual antagonism, both at the level of 
liver and gut13,18. In our current study, we were able to confirm this decreased hepatic NF-κ B activity following 
FXR agonism also in toxic cirrhotic rats. Moreover, we identified an up-regulation of the inhibitory protein Iκ Bα , 
which is known to sequester transcription factor NF-κ B as an inactive complex in the cytoplasm, as a molecular 
target of FXR agonist OCA48.
Translating the used experimental design into the human situation, this study suggests beneficial effects of 
OCA in both clinical settings. OCA attenuates inflammation and consequently fibrosis and portal hypertension 
in ongoing liver injury, such as it might occur in NASH or other intractable liver diseases. On the other side OCA 
reverses fibrosis and portal hypertension in the situation when the injuring agent was stopped such as it might 
occur in alcoholic and viral liver cirrhosis. While we have clearly illustrated an anti-inflammatory and subsequent 
anti-fibrotic effect in our different groups of experimental toxic cirrhosis, some unanswered questions remain. 
First, while the prophylactic and therapeutic arm of the study show many similarities, there seem to be differ-
ences in efficiency and cytokine expression pattern between both groups. Hypothetically, these might relate to the 
nature of the hepatotoxin used in our study. As such, we chose TAA, rather than CCl4, as it is more reflective of 
Figure 5. Effect of OCA on primary hepatocytes (HEP), liver sinusoidal endothelial cells (LSEC) and Kupffer 
cells (KC), in basal or LPS-/TNF-α-stimulated conditions. (A) The expression of MCP-1 is increased in 
hepatocytes following LPS- or TNF-α stimulation, yet remains unaffected by co-stimulation with OCA. (B) While 
in unstimulated LSEC, OCA does not affect the expression of pro-fibrotic cytokines such as TGF-β , it clearly 
prevents the increased expression of MCP-1 following in vitro stimulation with TNF-α . (C) While in unstimulated 
KC, OCA does not affect the expression of pro-inflammatory and pro-fibrotic cytokines; the expression of MCP-1 
is decreased following co-incubation with 10 μ M OCA. DMSO, dimethyl sulfoxide, vehicle; OCA, obeticholic 
acid; MCP-1, monocyte chemo-attractant protein-1; LPS, lipopolysaccharides; TGF-β , transforming growth 
factor-β ; TIMP-1, tissue inhibitor of metallopeptidase-1; FXR, Farnesoid-X receptor; IFN-γ , interferon-gamma; 
IL-10, interleukin-10; IL-6, interleukin-6; PDGF, platelet-derived growth factor.
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the human condition, e.g. alcoholic cirrhosis, since fibrogenesis is much slower in this model and the hepatotoxic 
insult is usually less severe and accompanied with a mild elevation in aminotransferases19,49. Secondarily, unlike 
in the CCl4-model, fibrosis did not spontaneously resolve, yet tended to increase further in OCA-untreated rats 
during 4 weeks after stopping the TAA compound and obtaining cirrhosis. In the preventive study, albeit a com-
parable significant decrease in fibrosis, these latter markers, apart from CTGF and TIMP-1, were less pronounced. 
A possible explanation is that the ongoing injury (i.e. TAA) antagonizes switch-off of PDGFβ -R, TGF-β and other 
earlier mentioned markers. On the other hand, the finding of decreased CTGF and TIMP-1 might reflect an 
initiation of an FXR-mediated antifibrotic effect, yet seem to be hampered in conditions of ongoing TAA intoxi-
cation50. Finally, we did not assess the role of different cell types in this particular context (such as cholangiocytes, 
dendritic cells and lymphocytes), which are also known to be involved in hepatic fibrogenesis; yet most of these 
cell types share the common NF-κ B pathway and have been shown to independently respond to FXR agonists in 
a similar fashion with decreased expression of pro-inflammatory cytokines in previous studies38,43.
In conclusion, we have shown for the first time that the FXR agonist OCA not only reduces hepatic fibrosis 
during ongoing cirrhogenesis, it also reverses fibrosis after obtaining cirrhosis in a rat model of toxic cirrhosis, 
resulting in decreased intrahepatic vascular resistance and improved portal hypertension. Unlike previous reports, 
this is not mediated by a direct effect on HSC, but rather through indirect effects on immune activation and 
hepatic cell turn-over, associated with a marked overall decrease in NF-κ B activation (through increased Iκ Bα ) 
and cytokines promoting fibrosis and inflammation within the liver parenchyma. In vitro, these effects could be 
reproduced in stimulated Kupffer cells and liver sinusoidal endothelial cells. These findings may in part explain 
the beneficial effects on hepatic fibrosis in recent phase 3 clinical trials with OCA in patients suffering from PBC 
and NASH and support extending clinical trials with FXR agonists to other forms of chronic liver injury51,52.
Figure 6. Hepatic NF-κB pathway activity in prophylactic and therapeutic study groups. (A) TransAM® 
assay showing decreased p65 activation indicative of NF-κ B pathway activity following OCA treatment in 
the therapeutic study arm. (B) Iκ Bα is increased significantly after OCA administration in the prophylactic 
study arm. NF-κ B, nuclear transcription factor-kappa beta; TAA, thioacetamide; OCA, obeticholic acid; Iκ Bα , 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.
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